Disease-Modifying Therapy Uptake in Transthyretin Amyloid Cardiomyopathy: A 10-Year US Analysis of 77,000 Patients Across Three Approved Agents.

Attruby (acoramidis) - BridgeBio

Vyndaqel (tafamidis meglumine) - Pfizer

Amvuttra (vutrisiran) - Alnylam

Disease-Modifying Therapy Uptake in Transthyretin Amyloid Cardiomyopathy: A 10-Year US Analysis of 77,000 Patients Across Three Approved Agents. (PubMed, J Nucl Cardiol) - Oct 15, 2026 - No abstract available
Journal • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular

http://www.ncbi.nlm.nih.gov/pubmed/42874836

David E Winchester; Krunal Shukla; Nisarg Ray

Oct 15, 2026